• Join SITC
  • Renew
Make a Gift
Skip to main content (Press Enter).
Sign in
Skip auxiliary navigation (Press Enter).
  • Subscribe
Society for Immunotherapy of Cancer (SITC) logo. This will take you to the homepage
Society for Immunotherapy of Cancer (SITC) logo. This will take you to the homepage
Skip main navigation (Press Enter).
  • Educational & Scientific Programs
      • ConnectED
      • Advances in Cancer Immunotherapy™
      • Collaborative Education Programs
      • 2023 Spring Scientific
      • Workshops
      • Tumor Immune Microenvironment: A Holistic Approach
      • Surfaceome Virtual Workshop
      • Bispecific T cell Engagers Virtual Workshop
      • Cytokines in Cancer Immunotherapy Virtual Workshop
      • Call for Proposals
      • Annual Meeting & Pre-Conference Programs
      • 37th Annual Meeting & Pre-Conference Programs
      • Past and Future Annual Meetings & Pre-Conference Programs
      • Cancer Immunotherapy Winter School
      • Patient and Survivor Education and Resources
      • Webinars and Online Education
      • ACI Online Interactive Courses
      • Advances in Cancer Immunotherapy (ACI) Webinars
      • Meet-the-Expert Webinars
      • SITC Clinical Practice Guidelines Online Education
      • SITC-NCI Computational IO Series
      • Targets for Cancer IO: A Deep Dive Series
      • Calendar of Events
  • Professional Development & Training
      • Certificate in Cancer Immunotherapy
      • Meet-the-Expert Program
      • Meet-the-Expert Webinars
      • NCI Immunotherapy Fellowship
      • SITC Sparkathon
      • SITC Sparkathon 2.0 Accelerator
      • Support Sparkathon
      • Other Resources
      • Calendar of Events
      • Path to SITC Leadership
      • Clinical Trials Training and Resources
      • SITC Clinical Immuno-Oncology Network (SCION) Workshop
      • Maximizing the Value of Phase III Trials in Immuno-Oncology
      • Professional Interest Communities
      • Fellowships
      • Women in Cancer Immunotherapy Network (WIN)
      • Women in Cancer Immunotherapy Network 2022
      • Women in SITC Community
      • Early Career Scientist (ECS) Committee
  • Publications & Guidelines
      • Journal for ImmunoTherapy of Cancer
      • About JITC
      • Become a Reviewer
      • For Authors
      • From the Editors
      • JITC Collections and Special Issues
      • SITC Immunotherapy Books
      • SITC's Guide to Managing Immunotherapy Toxicity Textbook
      • Cancer Immunotherapy Principles and Practice Textbook, 2nd Ed.
      • SITC Clinical Practice Guidelines
      • Clinical Practice Guidelines
      • Clinical Practice Guidelines Online Education
      • Clinical Practice Guidelines Mobile App
      • Patient Resource Guides
  • Policy & Advocacy
      • Advocacy
      • Crisis in Clinical Research
      • Global Immunotherapy Access
      • Government Relations
      • Quality and Value
      • Patient & Survivor Education & Resources
  • Membership
      • Academy of Immuno-Oncology
      • About the Academy
      • Nomination and Selection
      • Members Only
      • SITC Member Directory
      • Renew Your Membership
      • Become a SITC Member
      • Membership Benefits
      • Submit an Application
      • Membership Categories
      • Volunteer
      • Volunteer with SITC
      • Connect-a-Colleague
      • Corporate Membership
      • Path to SITC Leadership
  • Support SITC
      • The Forward Fund
      • Moving the Field Forward
      • Making a Difference
      • Named Funds and Awards
      • Early Career Scientist Awards
      • Richard V. Smalley Memorial Award and Lectureship
      • Steven A. Rosenberg Scholars Award
      • Technology Awards
      • Martin "Mac" Cheever Travel Award Fund
      • Sparkathon 2.0 Accelerator
      • The CheckPoints: SITC’s House Band
      • Ways to Make a Gift
      • Donate
      • Stocks and Securities
      • Estate and Planned Gifts
      • Corporate Support and Giving Opportunities
      • Corporate Giving Opportunities
      • Corporate Membership
      • Educational Grants
      • Sponsorship & Advertising
      • SITC Merchandise
      • Honor and Memorial Gifts
      • Make a Gift in Honor of a Loved One
      • Make a Gift in Memory of a Loved One
      • Our Donors and Supporters
      • 2022 SITC Supporters
      • Forward Fund Donors
  • About SITC
      • Awards and Recognition
      • Committees, Task Forces and Professional Interest Communities
      • Partnerships
      • SITC Policies
      • Board of Directors
      • Elevating a Rich Oncology Community: SITC’s DEI Strategic Plan
      • Media Room
      • SITC Press Releases
      • Scientific Meeting Highlights from SITC
      • Immune Monitor Archive
      • JITC Digest Archive
      • Cancer Immunotherapy Month
      • Career Connections
      • Mission & Vision
      • Contact SITC
      • SITC Staff
      • Contact Us
  • The Connect Community
      • Create Account
      • My Profile
      • My Communities
      • My Libraries
      • The Sentinel - SITC Blog

iSBTc 25th Annual Meeting

Annual Meeting Main Page  |  Annual Meeting Highlights  |   Program Purpose  |  Presentation Slides & Schedule
Faculty  |  Abstracts  |  Hot Topic Symposium |  Hot Topic Highlights  |  Award Recipients
Early Career Scientists  |   Session Goals  |  Final Program  |  Photos   |  Meeting Summary

Hot Topic Symposium:
CTLA-4 Blockade as a Cancer Therapeutic: How Do We Build on a Successful Foundation?

10:30am - 12:00pm
October 4, 2010
Hyatt Regency Washington on Capitol Hill
Washington, D.C.


Symposium Chair
James P. Allison, PhD
Memorial Sloan-Kettering Cancer Center

 

This cutting-edge session presented exciting new data on CTLA-4 blockade, including existing therapeutic combinations with anti-CTLA-4 that are poised for clinical use, potential future combinations, and insights into future directions in CTLA-4 blockade research and clinical translation.


Program Goals
  1. Present the latest pre-clinical and clinical data on CTLA-4 blockade in combination with other therapeutic agents.
  2. Explore future therapeutic combinations and clinical applications of CTLA-4 blockade for cancer treatment.
  3. Review clinical trial designs and biomarker endpoints to advance clinical translation of CTLA-4 blockade for cancer treatment.
  4. Explore directions for future research and application of CTLA-4 blockade in clinical oncology.
Intended Learner Outcomes
Upon completion of this meeting, participants will be able to:
  1. Discuss the latest clinical data on CTLA-4 blockade for cancer treatment.
  2. Identify promising therapeutic combinations with CTLA-4 blockade.
  3. Apply new considerations for clinical trial design and biomarkers in studies of CTLA-4 blockade.
  4. Identify productive new research directions to advance CTLA-4 blockade and improve cancer outcomes.

Schedule
To view slides from a presenter click the icon next to the presentation title.

10:30 am - 12:00 pm

Hot Topic Symposium:CTLA-4 Blockade as a Cancer Therapeutic: How Do We Build on a Successful Foundation?
10:35 - 10:55 am

Anti CTLA-4 Antibodies: Lessons Learned and Future Direction
Kevin Heller, MD - Bristol-Myers Squibb Company
10:55 - 11:15 am

Combination opportunities in immunotherapy with immunostimulatory mAb
Ignacio Melero, MD, PhD - University of Navarra
11:15 - 11:35 am

Exploring Therapeutic Combinations with Anti-CLTA-4 Antibody
Padmanee Sharma, MD, PhD - University of Texas, MD Anderson Cancer Center
11:35 am - Noon

Panel and Audience Discussion

 

Creative Commons License
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The Hot Topic Symposium is a non-accredited continuing medical education event. No credits are offered for physician participation in this educational program.

 




Membership Links

Join

Renew

Member Directory

My Profile

Get Involved

Email Sign-up

Volunteer

Support SITC

Contact Us

© 2024 Society for Immunotherapy of Cancer (SITC). All rights reserved.
555 East Wells Street, Suite 1100 | Milwaukee, WI | 53202-3823 | USA

Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: info@sitcancer.org

Powered by Higher Logic